The 36-month EFS rate was 84.5% for patients who received pembrolizumab and 76.8% for patients who received placebo.
(HR, 0.63; 95% CI, 0.48â€“0.82;P< .001).[107][Level of evidence B1]EFS data are immature.Grade 3 or higher adverse events occurred in 76.8% of participants in the pembrolizumab arm and 72.2% of participants in the placebo arm.
Serious treatment-related adverse events occurred in 32.5% of participants in the pembrolizumab arm and 19.5% of participants in the placebo arm.
Grade 3 or higher skin rashes, infusion reactions, and adrenal insufficiency were more frequent in the pembrolizumab arm.